SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Josh C. Pleasure, M.D. who wrote ()3/22/1998 8:27:00 PM
From: jluker  Read Replies (1) of 371
 
Josh, can you comment on this?
thanks

MORRIS PLAINS, N.J., March 22 (Reuters) - Biopharmaceutical
firm Immunomedics Inc. said on Friday it received U.S.
regulatory clearance to market a test kit to detect human
antibodies against mouse protein.
Patients with high human anti-mouse antibodies may be at
risk for anaphylactic shock or other allergic reactions, the
company said.
The U.S. Food and Drug Administration's Center for Devices
and Radiological Health approved the product for marketing in
the U.S., Immunomedics said.
Immunomedics' stock closed up 13/32 at 4-1/4 on Friday.
((New York Newsdesk (212) 859-1610, Fax (212) 859-1717))

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News